tbuckley/cabot-search huggingface dataset:
FRI0010 Effect of osteoprotegerin and pamidronate treatment in transgenic mice overexpressing human tnf-alpha
Authors: K Redlich, A Maier, S Hayer, G Kollias, CR Dunstan, S Lang, W Woloszczuk, G Steiner, J Smolen, G Schett
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Rheumatoid arthritis (RA) is characterised by progressive joint destruction resulting from chronic inflammation. Recent studies suggest that bone-resorbing osteoclasts formed in the synovium play an important role in bone destruction in RA. <h3>Objectives</h3> We studied the effect of anti-resorptive treatment with osteoprotegerin and/or pamidronate compared to TNF blockade with infliximab on the development of erosions in TNF overexpressing mice. <h3>Methods</h3> Systemic treatment with osteoprotegerin (OPG), pamidronate, both osteoprotegerin and pamidronate, infliximab or phosphate buffered saline (PBS) was carried out by intravenous injection. Treatment was initiated at the time of onset of arthritis and continued over 35d. Clinical, serological, radiological and histological outcomes were assessed after treatment. <h3>Results</h3> Clinical improvement, as assessed by reduction in paw swelling was only seen in the infliximab treated group. X-Rays of the hind paws were performed to quantify erosive changes. Erosions were detectable in each joint compartment Grading of erosions was performed analogous to the Larsen score. There was a marked and significant (p &lt; 0.05) reduction in the Larsen scores of mice treated with OPG (-54%), OPG and pamidronate (-64%) and infliximab (-66%). Microscopic examination of decalcified joint tissue sections using a semiquantitative method, revealed a significant (p &lt; 0.05) reduction in the extent of erosions in all treatment groups (OPG: -56%; pamidronate: -53%; OPG + pamidronate: -81%; infliximab ?46%) when compared to controls. <h3>Conclusion</h3> These data suggest that anti-resorptive treatment may have a significant potential in TNF-mediated bone destruction.
IMPACT OF RENAL DENERVATION ON PLASMA RENIN ACTIVITY AND RELATIONSHIP OF BASELINE PLASMA RENIN ACTIVITY TO BLOOD PRESSURE LOWERING RESPONSE TO RENAL DENERVATION IN THE SPYRAL HTN-OFF MED PIVOTAL TRIAL
Authors: Felix Mahfoud, Raymond Townsend, David Kandzari, Kazuomi Kario, Roland Schmieder, Konstantinos Tsioufis, Michael Boehm, Stuart Pocock, Sidney Cohen, Martin Fahy, Michael Weber
Journal: Journal of the American College of Cardiology (2021)
TCT CONNECT-228 In-hospital Outcomes of CTO PCI in Octogenarians and Nonagenarians: Insights From the PROGRESS-CTO Registry
Authors: Evangelia Vemmou, Khaldoon Alaswad, Mitul Patel, Ehtisham Mahmud, James Choi, Farouc Amin Jaffer, Anthony Doing, Dimitri Karmpaliotis, Oleg Krestyaninov, Dmitrii Khelimskii, Ilias Nikolakopoulos, Judit Karacsonyi, Iosif Xenogiannis, Santiago Garcia, M. Nicholas Burke, Nidal Abi Rafeh, Ahmed ElGuindy, Omer Goktekin, Abir Abdo, Bavana Rangan, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2020)
Using tobacco mosaic virus epitope display to enhance papillomavirus L2 antigen presentation
Authors: Alison A. McCormick, Long V. Nguyen, Sarah A. Venneman, Mark L. Smith, Patricia C. Edwards, Sherri Wykoff-Clary, Greg P. Pogue, Kenneth E. Palmer
Journal: Cancer Research (2004)

1267  Human papillomavirus (HPV), a family of pathogenic viruses, has been defined as the causal agent in cervical cancers, as well as a host of other human diseases. Cervical cancer incidence is rising at an alarming rate in third world countries, and there is great need for effective therapeutic and preventive vaccines for HPV. We are testing the ability of Tobacco Mosaic Virus (TMV) to function as a vaccine antigen carrier by displaying peptide epitopes on the surface of the TMV coat protein. TMV coat forms a semi-crystalline array of >2100 subunits around a non-integrating RNA, and molecular fusion of target epitopes to a surface-exposed region of TMV coat protein does not disrupt the TMV virus life cycle. Molecular fusion of epitopes to TMV coat, then, generates a high-density viral particle display of antigens that are ideally suited to stimulate high levels of specific immunogenicity. TMV is not pathogenic in mammalian hosts, and can be produced quickly and cost-effectively in plants. In these experiments, we created TMV fusions containing human or rabbit papillomavirus L2 minor capsid protein epitopes that have been shown previously to stimulate neutralizing immunity and protection from virus challenge (Embers et al, 2002, J. Immunol. 169, p350). TMV-peptide fusions were produced in tobacco plants by transient viral infection, extracted from whole tissue grinds, qualified for purity and identity, and then used to vaccinate mice at 10 μg per animal with no adjuvant. Specific immune responses to papillomavirus peptides were observed in all vaccines tested. Second generation vaccines are currently being developed that pair, on the surface of TMV, a papillomavirus antigen with a T-helper epitope, or a cellular fusion epitope, or both, in order to augment antigen uptake, processing and/or epitope-specific immunogenicity. Multivalent vaccines are being produced by molecular fusion, by chemical conjugation, or by both methods, and are being qualified and tested by similar methods as the mono-valent vaccines previously described. Vaccines that show improved immunogenicity in mice will be used to generate sera for virus neutralization studies, and for immunization of rabbits for viral challenge studies. TMV vaccines bearing a number of different CTL epitopes are being tested for their ability to stimulate specific T cell responses, as well as to prevent tumor outgrowth. Ultimately, we hope to develop a set of vaccines that can be used to either prevent or treat human papillomavirus disorders in a cost effective manner.
Return to Play for Athletes After Coronavirus Disease 2019 Infection—Making High-Stakes Recommendations as Data Evolve
Authors: James E. Udelson, Michael A. Curtis, Ethan J. Rowin
Journal: JAMA Cardiology (2020)

Jonathan H. Kim, MD, MSc; Benjamin D. Levine, MD; Dermot Phelan, MD, PhD; Michael S. Emery, MD, MS; Mathew W. Martinez, MD; Eugene H. Chung, MD, MSc; Paul D. Thompson, MD; Aaron L. Baggish, MD
Abstract 9869: Collagen-plug based Vascular Closure Devices can they Decrease Vascular and Bleeding Complications occurring After Balloon Aortic Valvuloplasty ?
Authors: Florence Leclercq, Delphine Delseny, Erika Nogue, Nicolas Nagot, Richard Gervasoni, Francois Roubille, Jean C Macia
Journal: Circulation (2013)

Introduction: Whereas they are controversial after coronary angioplasty, we assessed the hypothesis that the use of vascular closure devices (VCDs) after balloon aortic valvuloplasty (BAV), may decrease vascular and bleeding complications of the procedure. Methods: We conducted a prospective analysis of consecutive patients who underwent BAV in our center between 2009 and 2012. BAV was performed by femoral retrograde technique using 8 to 10 French sheaths. Group 1 consists of patients from which femoral puncture hemostasis was obtained with use of a 8 French collagen-plug based VCD (Angio-seal, St Jude Medical), group 2 consists of patients who have manual or mechanical compression (FemoStop, RADI Medical systems) of the femoral puncture site. We collected all major in-hospital adverse events, major bleeding (≥ BARC 3) and serious vascular access complications (pseudoanerysm, arterio venous fistula or acute limb ischemia). Results: Overall, 180 patients were included in that study. Indications for performing BAV included bridge to surgery (n=27), bridge to TAVI (n=71), therapy before extra cardiac surgery (n=35) or palliative (n=47). The two groups had similar median age (84 years) and previous lower extremity artery disease (overall n= 47, 26%, p=0.79). Vascular and bleeding complications occurred overall among 11.7% of the patients (n=21) and were more frequent in group 1 (p=0;02; table 1). Five of the 6 patients who suffered acute limb ischemia belonged to this group (p= 0.15). The rate of complications was the same whatever was the size if the sheath used. In conclusion, this study shows that collagen-plug based vascular closure devices increase vascular and bleeding complications occurring after balloon aortic valvuloplasty. Except in high risk bleeding patients, in whom femoral hemostasis can be difficult to obtain, the systematic use of these devices in a population of elderly patients with often advanced limb atherosclerosis, is questionable.
Multiscale Analysis of Extracellular Matrix Remodeling in the Failing Heart
Authors: Ana Rubina Perestrelo, Ana Catarina Silva, Jorge Oliver-De La Cruz, Fabiana Martino, Vladimír Horváth, Guido Caluori, Ondřej Polanský, Vladimír Vinarský, Giulia Azzato, Giuseppe de Marco, Víta Žampachová, Petr Skládal, Stefania Pagliari, Alberto Rainer, Perpétua Pinto-do-Ó, Alessio Caravella, Kamila Koci, Diana S. Nascimento, Giancarlo Forte
Journal: Circulation Research (2020)

Cardiac ECM (extracellular matrix) comprises a dynamic molecular network providing structural support to heart tissue function. Understanding the impact of ECM remodeling on cardiac cells during heart failure (HF) is essential to prevent adverse ventricular remodeling and restore organ functionality in affected patients.
iLBE for Computational Identification of Linear B-cell Epitopes by Integrating Sequence and Evolutionary Features
Authors: Md. Mehedi Hasan, Mst. Shamima Khatun, Hiroyuki Kurata
Journal: Genomics Proteomics & Bioinformatics (2020)

Linear B-cell epitopes are critically important for immunological applications, such as vaccine design, immunodiagnostic test, and antibody production, as well as disease diagnosis and therapy. The accurate identification of linear B-cell epitopes remains challenging despite several decades of research. In this work, we have developed a novel predictor, Identification of Linear B-cell Epitope (iLBE), by integrating evolutionary and sequence-based features. The successive feature vectors were optimized by a Wilcoxon-rank sum test. Then the random forest (RF) algorithm using the optimal consecutive feature vectors was applied to predict linear B-cell epitopes. We combined the RF scores by the logistic regression to enhance the prediction accuracy. iLBE yielded an area under curve score of 0.809 on the training dataset and outperformed other prediction models on a comprehensive independent dataset. iLBE is a powerful computational tool to identify the linear B-cell epitopes and would help to develop penetrating diagnostic tests. A web application with curated datasets for iLBE is freely accessible at http://kurata14.bio.kyutech.ac.jp/iLBE/.
Real‐world effectiveness and tolerability of dupilumab in adult atopic dermatitis: a single‐centre, prospective 1‐year observational cohort study of the first 100 patients treated
Authors: A.V. Sears, R.T. Woolf, E. Gribaleva, W. Abdelrahman, S. Robbie, B. Menon, B. Kirkham, C.H. Smith, A.E. Pink
Journal: British Journal of Dermatology (2020)

Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
Authors: Stéphanie Corgnac, Ines Malenica, Laura Mezquita, Edouard Auclin, Elodie Voilin, Jamila Kacher, Heloise Halse, Laetitia Grynszpan, Nicolas Signolle, Thibault Dayris, Marine Leclerc, Nathalie Droin, Vincent de Montpréville, Olaf Mercier, Pierre Validire, Jean-Yves Scoazec, Christophe Massard, Salem Chouaib, David Planchard, Julien Adam, Benjamin Besse, Fathia Mami-Chouaib
Journal: Cell Reports Medicine (2020)

Accumulation of CD103+CD8+ resident memory T (TRM) cells in human lung tumors has been associated with a favorable prognosis. However, the contribution of TRM to anti-tumor immunity and to the response to immune checkpoint blockade has not been clearly established. Using quantitative multiplex immunofluorescence on cohorts of non-small cell lung cancer patients treated with anti-PD-(L)1, we show that an increased density of CD103+CD8+ lymphocytes in immunotherapy-naive tumors is associated with greatly improved outcomes. The density of CD103+CD8+ cells increases during immunotherapy in most responder, but not in non-responder, patients. CD103+CD8+ cells co-express CD49a and CD69 and display a molecular profile characterized by the expression of PD-1 and CD39. CD103+CD8+ tumor TRM, but not CD103−CD8+ tumor-infiltrating counterparts, express Aiolos, phosphorylated STAT-3, and IL-17; demonstrate enhanced proliferation and cytotoxicity toward autologous cancer cells; and frequently display oligoclonal expansion of TCR-β clonotypes. These results explain why CD103+CD8+ TRM are associated with better outcomes in anti-PD-(L)1-treated patients.
AB0110 Pulmonary functional abnormalities in asymptomatic patients with systemic sclerosis
Authors: C Marcisz, AT Kotulska, EJ Kucharz, L Brzezinska-Wcislo, G Jonderko
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Systemic sclerosis (SSc) is a multisystem disease and pulmonary manifestations are common in SSc patients. Involvement of the lungs in SSc patients is detected with x-ray and functional pulmonary testing. The relationship of the development of the pulmonary abnormalities to duration of the disease and other organ involvement remains unclear. <h3>Objectives</h3> The present study was designed to determine the pulmonary function indices in the SSc patients without symptoms of the lung involvement. <h3>Methods</h3> Twenty-six women with definite diagnosis of SSc, aged 45.4+11.2 yrs were studied. Control values were obtained from 20 healthy age-matched women. Additionally, the SSc group was compared to the predicted spirometric data based on large population studies. The resting pulmonary function tests were performed with EDS-Sprint spirograph. The measurements were done between 8.00–9.00 AM. <h3>Results</h3> Vital capacity and maximal voluntary ventilation were decreased in the SSc patients. Forced vital capacity and one-second forced expiratory volume were also decreased but the later was normal when corrected for reduction of the forced vital capacity. Forced expiratory rate at 50% and 75% of forced vital capacity was impaired in the patients. Forced expiratory flow rate at 25% of forced vital capacity did not differ from the controls. The rate of incidence of abnormal pulmonary functional test in the SSc patients was 30–70 per cent. <h3>Conclusion</h3> Pulmonary involvement is common in SSc patients without overt manifestation of the lung disease. The lung function testing is a simple, cheap and safe method for evaluation of the respiratory system, and is recommended as a routine test for all patients with SSc.
TCT CONNECT-428 Micropuncture Technique for Femoral Access Associated With Lower Vascular Complications Compared With Standard 18-Gauge Needle Set
Authors: Avinash Sharma, Toby Rogers, Charan Yerasi, Brian Case, Chava Chezar-Azerrad, Anees Musallam, Brian Forrestal, Cheng Zhang, Hayder Hashim, Lowell Satler, Ron Waksman, Itsik Ben-Dor
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-211 ST-Segment Elevation is Associated With Worse Outcomes in Patients Hospitalized With COVID-19: Large System-Wide Analysis of Clinical Characteristic and Outcomes
Authors: Avneet Singh, Luis Gruberg, Rajiv Jauhar, Puneet Gandotra, Arvind Reddy Devanabanda, Stavros Mountantonakis
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-470 Novel Method for Implantation of Balloon Expandable Transcatheter Aortic Valve Replacement to Reduce Pacemaker Rate—Line of Lucency Method
Authors: P. Kasi Ramanathan, Salik Nazir, Ahmed Elzanaty, Zeid Nesheiwat, Muhammad Mahmood, Roberta E. Redfern
Journal: Journal of the American College of Cardiology (2020)
TCT CONNECT-372 Outcomes in Patients with Peripheral Arterial Disease and Concomitant Atrial Fibrillation: A Population-Based Study
Authors: Sundeep Kumar, Akhil Mogalapalli, Ali Ghani, Zachary Oman, Mariam Baig, Ruthvik Srinivasamurthy, Philip Mar, Ammar Nasir
Journal: Journal of the American College of Cardiology (2020)
Pancreatic QST Differentiates Chronic Pancreatitis Patients into Distinct Pain Phenotypes Independent of Psychiatric Comorbidities
Authors: Mahya Faghih, Anna E. Phillips, Louise Kuhlmann, Elham Afghani, Asbjørn M. Drewes, Dhiraj Yadav, Vikesh K. Singh, Søren S. Olesen
Journal: Clinical Gastroenterology and Hepatology (2020)
Association of Therapies With Reduced Pain and Improved Quality of Life in Patients With Fibromyalgia
Authors: Rodrigo Oliveira Mascarenhas, Mateus Bastos Souza, Murilo Xavier Oliveira, Ana Cristina Lacerda, Vanessa Amaral Mendonça, Nicholas Henschke, Vinícius Cunha Oliveira
Journal: JAMA Internal Medicine (2020)

<h3>Importance</h3> Fibromyalgia is a chronic condition that results in a significant burden to individuals and society. <h3>Objective</h3> To investigate the effectiveness of therapies for reducing pain and improving quality of life (QOL) in people with fibromyalgia. <h3>Data Sources</h3> Searches were performed in the MEDLINE, Cochrane, Embase, AMED, PsycInfo, and PEDro databases without language or date restrictions on December 11, 2018, and updated on July 15, 2020. <h3>Study Selection</h3> All published randomized or quasi-randomized clinical trials that investigated therapies for individuals with fibromyalgia were screened for inclusion. <h3>Data Extraction and Synthesis</h3> Two reviewers independently extracted data and assessed risk of bias using the 0 to 10 PEDro scale. Effect sizes for specific therapies were pooled using random-effects models. The quality of evidence was assessed using the Grading of Recommendations Assessment (GRADE) approach. <h3>Main Outcomes and Measures</h3> Pain intensity measured by the visual analog scale, numerical rating scales, and other valid instruments and QOL measured by the Fibromyalgia Impact Questionnaire. <h3>Results</h3> A total of 224 trials including 29 962 participants were included. High-quality evidence was found in favor of cognitive behavioral therapy (weighted mean difference [WMD], −0.9; 95% CI, −1.4 to −0.3) for pain in the short term and was found in favor of central nervous system depressants (WMD, −1.2 [95% CI, −1.6 to −0.8]) and antidepressants (WMD, −0.5 [95% CI, −0.7 to −0.4]) for pain in the medium term. There was also high-quality evidence in favor of antidepressants (WMD, −6.8 [95% CI, −8.5 to −5.2]) for QOL in the short term and in favor of central nervous system depressants (WMD, −8.7 [95% CI, −11.3 to −6.0]) and antidepressants (WMD, −3.5 [95% CI, −4.5 to −2.5]) in the medium term. However, these associations were small and did not exceed the minimum clinically important change (2 points on an 11-point scale for pain and 14 points on a 101-point scale for QOL). Evidence for long-term outcomes of interventions was lacking. <h3>Conclusions and Relevance</h3> This systematic review and meta-analysis suggests that most of the currently available therapies for the management of fibromyalgia are not supported by high-quality evidence. Some therapies may reduce pain and improve QOL in the short to medium term, although the effect size of the associations might not be clinically important to patients.
Bioinformatic analysis of RHO family of GTPases identifies RAC1 pharmacological inhibition as a new therapeutic strategy for hepatocellular carcinoma
Authors: Juan Bayo, Esteban J Fiore, Luciana María Dominguez, María Jose Cantero, Matias S Ciarlantini, Mariana Malvicini, Catalina Atorrasagasti, Mariana Gabriela Garcia, Mario Rossi, Claudio Cavasotto, Elisabeth Martinez, Julieta Comin, Guillermo D Mazzolini
Journal: Gut (2020)

Objective The RHO family of GTPases, particularly RAC1, has been linked with hepatocarcinogenesis, suggesting that their inhibition might be a rational therapeutic approach. We aimed to identify and target deregulated RHO family members in human hepatocellular carcinoma (HCC). Design We studied expression deregulation, clinical prognosis and transcription programmes relevant to HCC using public datasets. The therapeutic potential of RAC1 inhibitors in HCC was study in vitro and in vivo. RNA-Seq analysis and their correlation with the three different HCC datasets were used to characterise the underlying mechanism on RAC1 inhibition. The therapeutic effect of RAC1 inhibition on liver fibrosis was evaluated. Results Among the RHO family of GTPases we observed that RAC1 is upregulated, correlates with poor patient survival, and is strongly linked with a prooncogenic transcriptional programme. From a panel of novel RAC1 inhibitors studied, 1D-142 was able to induce apoptosis and cell cycle arrest in HCC cells, displaying a stronger effect in highly proliferative cells. Partial rescue of the RAC1-related oncogenic transcriptional programme was obtained on RAC1 inhibition by 1D-142 in HCC. Most importantly, the RAC1 inhibitor 1D-142 strongly reduce tumour growth and intrahepatic metastasis in HCC mice models. Additionally, 1D-142 decreases hepatic stellate cell activation and exerts an anti-fibrotic effect in vivo. Conclusions The bioinformatics analysis of the HCC datasets, allows identifying RAC1 as a new therapeutic target for HCC. The targeted inhibition of RAC1 by 1D-142 resulted in a potent antitumoural effect in highly proliferative HCC established in fibrotic livers.
MOF Drug Carriers: Biodegradable Metal–Organic Framework‐Based Microrobots (MOFBOTs) (Adv. Healthcare Mater. 20/2020)
Authors: Anastasia Terzopoulou, Xiaopu Wang, Xiang‐Zhong Chen, Mario Palacios‐Corella, Carlos Pujante, Javier Herrero‐Martín, Xiao‐Hua Qin, Jordi Sort, Andrew J. deMello, Bradley J. Nelson, Josep Puigmartí‐Luis, Salvador Pané
Journal: Advanced Healthcare Materials (2020)

In article number 2001031 by Xiang-Zhong Chen, Josep Puigmartí-Luis, and co-workers, highly integrated MOFBOTs are developed for targeted drug delivery. Fe@ZIF-8, a magnetic MOF composite synthesized via a one-pot procedure, plays a dual role of drug carrier and motile component of the microrobot. pH-triggered degradation of the MOF and enzymatic degradation of the gelatin-based chassis result in an overall degradable system, which opens new avenues for highly integrated fully biodegradable small-scale robots.